The treatment of<unk> es depends foremost on the nature of the abnormality. Somatic treatment of<unk> ly genetic defects is in its infancy. Most treatment is therefore passive and palliative, and falls into two modalities: managing infections and boosting the immune system. Reduction of exposure to pathogens may be recommended, and in many situations prophylactic antibiotics or antivirals may be advised. In the case of humoral immune deficiency, immunoglobulin replacement therapy in the form of intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) may be available. In cases of autoimmune disorders, immunosuppression therapies like corticosteroids may be prescribed. For<unk> es that are caused by genetic mutation does not exist a causal therapy that would "repair" the mutation. Although there is a therapeutic option, gene therapy which has been in a trial for few immune deficiencies affecting the hematopoietic system. Over the past two decades there were some successful treatments of patients with specific<unk> es <unk> , including X-linked severe combined immunodeficiency (SCID), Wiskott–Aldrich syndrome and metabolic conditions such as leukodystrophy. Gene therapy evolved in the 90s from using of gammaretroviral vectors to more specific self-inactivating vector platforms around 2006. The viral vectors randomly insert their sequences into the genomes. However, it is rarely used because of a risk of developing post-treatment T-cell leukemia as a result of interfering tumor-suppressor genes and because of ethical issues. But the progress in gene therapy is promising for the future of treating<unk> es.
Primary immunodeficiency
Combined immunodeficiencies
Severe combined immunodeficiency
Selective immunoglobulin A deficiency
Common variable immunodeficiency
IgG deficiency
X-linked agammaglobulinemia
Adult-onset immunodeficiency syndrome